Expand all sections

Rifaximin

Xifaxan

Extended indication Prikkelbaredarmsyndroom
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Rifaximin
Domain Chronic immune diseases
Main indication Bowel diseases
Extended indication Prikkelbaredarmsyndroom
Proprietary name Xifaxan
Manufacturer Norgine
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Dit betreft een antibioticum dat al beschikbaar is in Nederland.

Registration

Registration route Centralised (EMA)
Particularity Indication extension
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
Frequency of administration 2 times a day
Dosage per administration 550 mg

Expected patient volume per year

References NHG-Standaard Prikkelbaredarmsyndroom (PDS)
Additional remarks De prevalentie is voor mannen 4 per 1000 en voor vrouwen 10 per 1000. (NHG). 17 mln*14/2000= 119.000 personen maximaal. Onduidelijk welk deel van deze populatie in aanmerking komt.

Expected cost per patient per year

Cost 4,500.00
References Medicijnkosten.nl
Additional remarks €6,08 per pil van 550mg. € 4441,06 pppj

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.